Parkinson's disease, L-DOPA, and endogenous morphine: a revisit

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F12%3A13387" target="_blank" >RIV/00216208:11110/12:13387 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/12:8211 RIV/00216208:11140/12:10123255 RIV/00064203:_____/12:8211
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Parkinson's disease, L-DOPA, and endogenous morphine: a revisit
Original language description
Clinical observations stemming from widespread employment of restorative L-3,4-dihydroxyphenylalanine (L-DOPA) therapy for management of dyskinesia in Parkinson's Disease (PD) patients implicate a regulatory role for endogenous morphine in central nervous system dopamine neurotransmission. Reciprocally, it appears that restorative L-DOPA administration has provided us with a compelling in vivo pharmacological model for targeting peripheral sites involved in endogenous morphine expression in human subjects. The biological activities underlying endogenous morphine expression and its interaction with its major precursor dopamine strongly suggest that endogenous morphine systems are reciprocally dysregulated in PD. These critical issues are examined from historical and current perspectives within our short review.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FL - Psychiatry, sexology
OECD FORD branch
—

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)